Lantheus Holdings (LNTH)

$LNTH Ain't gonna matter but voted full Against this scammy golden parachute crew. Y'all can foogoff.

$CATX Once $LNTH is done with their dumping, we can start to move back up.

Who most likely would acquire $CATX after ESMO in October. $LNTH $NVS $BMS $TLX https://chatgpt.com/s/m_6a9337ce252081918e281cbb196a9762

explains (in part, at least) why in July RADX went straight to financing/raising capital along with RAD101 final Ph2b readout I’m still not happy with how leadership went about this overall given potential and results of RAD101 optimistic/apologetic view and explanation: is that perhaps Lantheus acquisition complicated any RAD101 licensing/partnership deals in the works and now requires that dust on LNTH acquisition and Curium portfolio review settles before confirming what’s the best way to proceed and who the best partner is this detail coming out provides some comfort in that they really had no other choice — selfishly, I wish they would have let the news run and use ATM/warrants to raise capital but with only 4m cash on hand the uncertainty and timing surrounding this still too risky and it needed to be settled ahead of time $RADX $LNTH

There is one genuinely interesting Lu-177 story today (Aug. 25), and I think it has a positive read-through for $RADX Curium $LNTH explicitly making the case for Lu-177 BioSpace published an interview today with Curium North America CEO Michael Patterson about Curium's ¹⁷⁷Lu-PSMA-I&T, its direct Lu-177 competitor to Novartis' Pluvicto. Curium's Phase 3 already met its primary endpoint, and the company is preparing to work with the FDA on filing/review. The interesting part for RADX is that despite all the excitement around Ac-225, Curium is still investing heavily in Lu-177 and believes physicians and patients want additional Lu-177 options. Curium is emphasizing manufacturing capacity and supply reliability as a competitive advantage. That's supportive of RAD202 and RAD204 because it reinforces that sophisticated radiopharma companies don't view Lu-177 as an isotope that's about to become obsolete because of alpha emitters.

The Sleeping Radiopharmaceutical Giant $RADX $CATX $AKTS $LNTH Source: ChatGPT https://chatgpt.com/c/6a8aee30-e7ac-83ea-97e2-71a84590002d

$RADX RAD204 onto Something? $CATX $LNTH $IOVA https://chatgpt.com/s/m_6a862051fca48191a45640f7f9aa8e0d

Radiopharm Theranostics Nasdaq: $RADX has scheduled an End-of-Phase 2 meeting with the U.S. FDA on October 1, 2026 to align on the design of a pivotal Phase 3 trial of RAD101 in patients with suspected recurrent brain metastases following radiotherapy. According to the company, its Phase 2b trial of RAD101 showed 93% concordance between MRI and PET imaging across evaluable lesions, meeting the primary endpoint and demonstrating substantial, selective tumor uptake. RAD101 has FDA Fast Track Designation, and a partnership with Siemens Healthineers will supply 18F-labeled RAD101 for the planned U.S. Phase 3 registrational trial, which Radiopharm aims to have Phase 3-ready by year-end 2026. $LNTH $AKTS $CATX

$LNTH what a scam job by this management. Just gave CO away with I'm sure a large golden parachute.

$LNTH $CAPR $NVDA Fda approved $LNTH

$LNTH $SPY $BMY Finally FDA Approved $LNTH

$LNTH FDA Approved $CAPR

$LNTH FDA APPROVED, but didn’t go the max price 112$

Unicycive Therapeutics, Inc. (Nasdaq: $UNCY ) announced in its second quarter 2026 business update that the U.S. Food and Drug Administration has assigned a facility inspection to the third-party manufacturing vendor for oxylanthanum carbonate (OLC), its investigational phosphate binding agent for hyperphosphatemia in patients with chronic kidney disease on dialysis. Unicycive Therapeutics, Inc. is a B2i Digital (@B2iDigital) Featured Company. See the company’s in-depth profile at: https://b2idigital.com/unicycive The second quarter update sets out the next step in the OLC regulatory pathway and the cash position behind it: • The company expects to resubmit the New Drug Application for OLC assuming completion of a successful inspection of that vendor • Unaudited cash, cash equivalents and marketable securities totaled $61.4 million as of June 30, 2026, with expected runway into 2027 • The FDA has not raised any concerns regarding clinical efficacy or safety data for OLC, and requested no additional data • Commercial readiness work continues, focused on patient access and the UniSource reimbursement hub Regarding the inspection, Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, stated: “The latest update from our third-party manufacturing vendor is that the U.S. Food and Drug Administration (FDA) has assigned a facility inspection. This marks a positive step forward, and our dialogue with the FDA on OLC labeling and packaging has been productive and continuous throughout this process.” Read the full release: https://ir.unicycive.com/news/detail/124/unicycive-therapeutics-announces-second-quarter-2026 The company will engage the patient and clinical community at the 51st Annual American Association of Kidney Patients National Patient Meeting in Little Rock, Arkansas, September 11 to 13, and the 2026 Renal Healthcare Association Annual Conference in Savannah, Georgia, September 23 to 26. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Its lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. A second investigational treatment, UNI-494, is intended for conditions related to acute kidney injury, has been granted orphan drug designation by the FDA for the prevention of Delayed Graft Function in kidney transplant patients, and has completed a Phase 1 dose-ranging safety study in healthy volunteers. Learn more at https://unicycive.com. Discover more emerging growth Featured Companies, Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $XOMA, $RMTI, $LNTH, $XBI

$RADX potential takeover candidate by Curium - synergies and valuation by AI $LNTH https://chatgpt.com/s/m_6a7c70ca67dc81918efa0a23552b552a

$LNTH literally gotta hold this pile of junk for 6-8mo for 2$ and some whack 12$ CVR.

$RADX Yes, Curium could have a substantial interest in Radiopharm Theranostics’ RAD101, as it perfectly fits Curium's immediate commercial objective of acquiring late-stage, high-margin radiodiagnostics CapVest News, FirstWord Pharma.Following its recent $8 billion merger agreement with Lantheus CapVest News, Curium is actively expanding its diagnostic reach Radiology Business. RAD101 (¹⁸F-Pivalate) matches their exact operational blueprint for three primary reasons FirstWord Pharma $LNTH

$FLNC $FSLY $LNTH $OCUL $SPRY no they don’t. They r falling off the cliff

$TLX Australian radiopharma to host its "coming out party" to American investors Sept 22nd R&D Day (quite timely after $LNTH buyout) Whereas prior presentations focused on a specific business segment, mgmt + KOLs will showcase their full portfolio of diagnostics & therapeutics + manufacturing capabilities (moat)

$LNTH Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.15 • Reported revenue of $388.18M up 2.68% YoY

$LNTH Talk about f….g over shareholders. Hope the ambulance chaser make the boards life miserable. Leaches